Literature DB >> 10381490

Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis.

T Sekine1, T Kato, K Masuko-Hongo, H Nakamura, S Yoshino, K Nishioka, K Yamamoto.   

Abstract

OBJECTIVE: To investigate whether type II collagen (CII) is recognised by oligoclonally expanded synovial T cells of patients with rheumatoid arthritis (RA).
METHODS: Peripheral blood mononuclear cells (PBMC) from 15 RA patients were stimulated with CII in vitro. T cell clones expanded by such stimulation were compared with the clonally expanded synovial T cells by using T cell receptor (TCR) B chain gene specific reverse transcription-polymerase chain reaction and subsequent single strand conformation polymorphism analyses.
RESULTS: Stimulation of the heterogeneous peripheral T cells with CII induced clonal expansion of T cells. In three of 15 patients, a proportion of these clones (approximately 17% to 25%) was found to be identical to expanded T cell clones in the synovium in vivo.
CONCLUSION: T cell clones that had TCR CDR3 sequences identical to those induced by purified CII were found in a proportion of RA patients. This finding suggests that CII is recognised by T cells that accumulate clonally in RA joints. Oligoclonal T cell expansion in RA joints is probably driven, at least in part, by intra-articular components such as CII.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381490      PMCID: PMC1752913          DOI: 10.1136/ard.58.7.446

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model.

Authors:  E S M El-Denshary; L A Rashed; M Elhussiny
Journal:  Clin Exp Med       Date:  2013-08-30       Impact factor: 3.984

3.  Cytotoxic T lymphocytes recognize and lyse chondrocytes under inflammatory, but not non-inflammatory conditions.

Authors:  E Suzanne Cohen; Helen C Bodmer
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

4.  Effect of IL15 on T cell clonality in vitro and in the synovial fluid of patients with rheumatoid arthritis.

Authors:  K Masuko-Hongo; M Kurokawa; T Kobata; K Nishioka; T Kato
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

5.  Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift.

Authors:  Jian Sun; Yuan Jia; Ru Li; Jianping Guo; Xiaolin Sun; Yanying Liu; Yingni Li; Haihong Yao; Xia Liu; Jing Zhao; Zhanguo Li
Journal:  Cell Mol Immunol       Date:  2011-03-07       Impact factor: 11.530

6.  The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.

Authors:  Jinan Li; Annelii Ny; Göran Leonardsson; Kutty Selva Nandakumar; Rikard Holmdahl; Tor Ny
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Authors:  Xiaolei Tang; David E Yocum; David Dejonghe; Kathryn Nordensson; Douglas F Lake; John Richard
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

8.  Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis.

Authors:  Fei Mao; Wen-Rong Xu; Hui Qian; Wei Zhu; Yong-Min Yan; Qi-Xiang Shao; Hua-Xi Xu
Journal:  Inflamm Res       Date:  2009-09-10       Impact factor: 4.575

9.  Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis.

Authors:  Francesco Ria; Romina Penitente; Maria De Santis; Chiara Nicolò; Gabriele Di Sante; Massimiliano Orsini; Dario Arzani; Andrea Fattorossi; Alessandra Battaglia; Gian Franco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2008-11-17       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.